Regarding metastatic disease, very few and contradictory data are available.15,16 Considering the new emerging therapies for ERBB2-low BC, especially in a metastatic setting, a better description of the epidemiology, response to treatment, and outcomes of that population seems important. The gene discussed is ERBB2; the disease is breast cancer.